Ligand Specific Efficiency (LSE) Index for PET Tracer Optimization

被引:18
作者
Auberson, Yves P. [1 ]
Briard, Emmanuelle [1 ]
Sykes, David [2 ]
Reilly, John [3 ]
Healy, Mark [3 ]
机构
[1] Novartis Inst BioMed Res, Klybeckstr 141, CH-4057 Basel, Switzerland
[2] Univ Nottingham, Cell Signalling Dept, Nottingham NG7 2RD, England
[3] Novartis Inst BioMed Res, 250 Massachusetts Ave, Cambridge, MA 02139 USA
关键词
imaging agents; inhibitor design; ligand efficiency; medicinal chemistry; prostacyclin receptor; POSITRON-EMISSION-TOMOGRAPHY; IN-VIVO; ACETYLCHOLINESTERASE INHIBITORS; RECEPTOR-BINDING; AFFINITY; HYDROCHLORIDE; PARAMETERS; DISCOVERY; ALIGNMENT; ASSAY;
D O I
10.1002/cmdc.201600112
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Ligand efficiency indices are widely used to guide chemical optimization in drug discovery, due to their predictive value in the early steps of optimization. At later stages, however, as more complex properties become critical for success, indices relying on calculated, rather than experimental, parameters become less informative. This problem is particularly acute when developing positron emission tomography (PET) imaging agents, for which nonspecific binding (NSB) to membranes and non-target proteins is a frequent cause of failure. NSB cannot be predicted using insilico parameters. To address this gap, we explored the use of the experimentally determined chromatographic hydrophobicity index on immobilized artificial membranes, CHI(IAM), to guide the optimization of NSB. The ligand specific efficiency (LSE) index was defined as the ratio between affinity (pIC(50) or pK(d)) and the logarithmic value of CHI(IAM). It allows for quantification of binding affinity to the target of interest, relative to NSB. Its use was illustrated by the optimization of PET tracer candidates for the prostacyclin receptor.
引用
收藏
页码:1415 / 1427
页数:13
相关论文
共 28 条
[1]   Label-free assay for the assessment of nonspecific binding of positron emission tomography tracer candidates [J].
Assmus, Frauke ;
Seelig, Anna ;
Gobbi, Luca ;
Borroni, Edilio ;
Glaentzlin, Patricia ;
Fischer, Holger .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 79 :27-35
[2]   Estimation of Drug Binding to Brain Tissue: Methodology and in Vivo Application of a Distribution Assay in Brain Polar Lipids [J].
Belli, Sara ;
Assmus, Frauke ;
Wagner, Bjoem ;
Honer, Michael ;
Fischer, Holger ;
Schuler, Franz ;
Alvarez-Sanchez, Ruben .
MOLECULAR PHARMACEUTICS, 2015, 12 (12) :4529-4541
[3]  
Bley K. R., 1999, Eur. Pat., Patent No. [EP0902018A3, 0902018]
[4]  
BUNZOW JR, 1995, J NEUROCHEM, V64, P14
[5]   Miniaturized receptor binding assays: Complications arising from ligand depletion [J].
Carter, Clare M. Scaramellini ;
Leighton-Davies, Juliet R. ;
Charlton, Steven J. .
JOURNAL OF BIOMOLECULAR SCREENING, 2007, 12 (02) :255-266
[6]  
Cella C. V., 2004, 4 FOR EUR NEUR LISB, V2
[7]   Discovery and SAR development of 2-(phenylamino) imidazolines as postacyclin receptor antagonists [J].
Clark, RD ;
Jahangir, A ;
Severance, D ;
Salazar, R ;
Chang, T ;
Chang, D ;
Jett, MF ;
Smith, S ;
Bley, K .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (04) :1053-1056
[8]  
Donahich G. P., 1985, EUR J PHARMACOL, V119, P9
[9]  
Frank R, 2013, Patent Application, Patent No. [WO2013068461, 2013068461]
[10]  
GIROS B, 1992, MOL PHARMACOL, V42, P383